Send to

Choose Destination
Probiotics Antimicrob Proteins. 2018 Mar 5. doi: 10.1007/s12602-018-9401-3. [Epub ahead of print]

Effect of a Preparation of Four Probiotics on Symptoms of Patients with Irritable Bowel Syndrome: Association with Intestinal Bacterial Overgrowth.

Author information

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Hepatogastroenterology Unit, 2nd Department of Internal Medicine-Propedeutic, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, Greece.
4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
4th Department of Internal Medicine, ATTIKON University Hospital, 1 Rimini Street, 1262, Athens, Greece.


The effect of probiotics on small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome (IBS) has never been studied so far. In this prospective trial, five patients with IBS and SIBO and 21 patients with IBS without SIBO were administered an oral capsule containing Saccharomyces boulardii, Bifidobacterium lactis, Lactobacillus acidophilus, and Lactobacillus plantarum (Lactolevure®) every 12 h for 30 days. SIBO was defined by quantitative culture of the third part of the duodenum; IBS was defined by the Rome III criteria. Severity of symptoms was graded by the IBS severity scoring system (SSS). The primary study endpoint was the efficacy of probiotics in improvement of symptoms of IBS in patients with SIBO. Thirty days after the end of treatment, a 71.3% decrease of the total IBS score was detected in patients with IBS and SIBO compared to 10.6% in those without SIBO (p 0.017). A similar decrease was achieved among patients with constipation-predominant IBS without SIBO. Post-treatment satisfaction from bowel function was greater in patients with SIBO. Similar satisfaction improvement was found among patients with diarrhea-predominant IBS irrespective from SIBO; pain intensity score decreased in patients with constipation-predominant IBS irrespective from SIBO. The benefit of probiotics was greater among patients with a pro-inflammatory cytokine pattern in the duodenal fluid. This is the first study that prospectively demonstrated superior clinical efficacy of probiotics in patients with IBS with SIBO. Analysis also showed considerable benefit from probiotic intake regarding certain symptoms of patients with diarrhea-predominant and constipation-predominant IBS.

TRIAL REGISTRATION: identifier NCT02204891.


Intestinal bacterial overgrowth; Irritable bowel syndrome; Probiotics


Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center